We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Regeneron (REGN) Q2 Earnings: Can the Stock Surprise?
Read MoreHide Full Article
Regeneron Pharmaceuticals, Inc. (REGN - Free Report) is scheduled to release second-quarter 2016 results on Aug 4, before the opening bell. The company’s performance so far has been mixed. In the last four reported quarters, the company has surpassed earnings estimates on two occasions while it missed in the other two. Overall, the company has recorded an average negative earnings surprise of 0.06%.
Last quarter, the company recorded a positive earnings surprise of 16.94%. Let’s see how things are shaping up for this announcement.
Will Eylea Continue to Drive Revenues?
Regeneron’s key growth driver, Eylea, should continue to perform well in the second quarter of 2016 and contribute meaningfully to the company’s top line. In the first quarter of 2016, the company continued to witness strong sales growth for Eylea, both in the U.S. and abroad. While U.S. sales of the drug surged 44% year over year, it increased approximately 5% sequentially driven by market share gains.
Product revenue from ex-U.S. Eylea sales is recorded by Bayer AG (BAYRY - Free Report) . We note that Regeneron has a global development and commercialization agreement with Bayer outside the U.S. for Eylea.
Encouraged by the strong performance of the eye drug, the company raised the Eylea U.S. net sales guidance for 2016. It is expected to grow 20–25% in 2016. Previously, the company had anticipated Eylea sales to grow approximately 20%.
Apart from Eylea, investor focus will remain primarily on the performance of the PCSK9 inhibitor, Praluent. We note that Regeneron has co-developed Praluent with Sanofi (SNY - Free Report) . While Praluent's launch is currently underway, Regeneron noted on the first-quarter call that the product is facing a difficult reimbursement environment outside the U.S.
On the second-quarter call, focus will be on the company’s performance including the eye drug and Praluent along with pipeline updates.
Earnings Whispers
Our proven model does not conclusively show that Regeneron is likely to beat earnings estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) for this to happen. However, that is not the case here, as you will see below.
Zacks ESP: The Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is 0.00%. This is because both the Most Accurate estimate and the Zacks Consensus Estimate stand at $1.73 per share.
Zacks Rank: Regeneron currently carries a Zacks Rank #3, which when combined with an ESP of 0.00%, makes a surprise prediction difficult.
Note that we caution against stocks with a Zacks Rank #4 or 5 (Sell-rated stocks) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Here is a health care stock that you may want to consider instead, as our model shows that it has the right combination of elements to post an earnings beat this quarter:
Conatus Pharmaceuticals Inc. has an Earnings ESP of +5.41% and a Zacks Rank #3. The company is scheduled to release second-quarter results on Aug 3.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Regeneron (REGN) Q2 Earnings: Can the Stock Surprise?
Regeneron Pharmaceuticals, Inc. (REGN - Free Report) is scheduled to release second-quarter 2016 results on Aug 4, before the opening bell. The company’s performance so far has been mixed. In the last four reported quarters, the company has surpassed earnings estimates on two occasions while it missed in the other two. Overall, the company has recorded an average negative earnings surprise of 0.06%.
Last quarter, the company recorded a positive earnings surprise of 16.94%. Let’s see how things are shaping up for this announcement.
Will Eylea Continue to Drive Revenues?
Regeneron’s key growth driver, Eylea, should continue to perform well in the second quarter of 2016 and contribute meaningfully to the company’s top line. In the first quarter of 2016, the company continued to witness strong sales growth for Eylea, both in the U.S. and abroad. While U.S. sales of the drug surged 44% year over year, it increased approximately 5% sequentially driven by market share gains.
Product revenue from ex-U.S. Eylea sales is recorded by Bayer AG (BAYRY - Free Report) . We note that Regeneron has a global development and commercialization agreement with Bayer outside the U.S. for Eylea.
Encouraged by the strong performance of the eye drug, the company raised the Eylea U.S. net sales guidance for 2016. It is expected to grow 20–25% in 2016. Previously, the company had anticipated Eylea sales to grow approximately 20%.
Apart from Eylea, investor focus will remain primarily on the performance of the PCSK9 inhibitor, Praluent. We note that Regeneron has co-developed Praluent with Sanofi (SNY - Free Report) . While Praluent's launch is currently underway, Regeneron noted on the first-quarter call that the product is facing a difficult reimbursement environment outside the U.S.
On the second-quarter call, focus will be on the company’s performance including the eye drug and Praluent along with pipeline updates.
Earnings Whispers
Our proven model does not conclusively show that Regeneron is likely to beat earnings estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) for this to happen. However, that is not the case here, as you will see below.
Zacks ESP: The Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is 0.00%. This is because both the Most Accurate estimate and the Zacks Consensus Estimate stand at $1.73 per share.
Zacks Rank: Regeneron currently carries a Zacks Rank #3, which when combined with an ESP of 0.00%, makes a surprise prediction difficult.
Note that we caution against stocks with a Zacks Rank #4 or 5 (Sell-rated stocks) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
REGENERON PHARM Price and EPS Surprise
REGENERON PHARM Price and EPS Surprise | REGENERON PHARM Quote
A Stock That Warrants a Look
Here is a health care stock that you may want to consider instead, as our model shows that it has the right combination of elements to post an earnings beat this quarter:
Conatus Pharmaceuticals Inc. has an Earnings ESP of +5.41% and a Zacks Rank #3. The company is scheduled to release second-quarter results on Aug 3.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>